Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Response Features Following Vaccination With a Recombinant RSV Vaccine
NCT07618325Not yet recruiting
- Sponsor
- MAXVAX Biotechnology
- Start
- Jun 2026
- Primary completion
- Jun 2028
01
Overview
Open-label, single-arm trial of recombinant respiratory syncytial virus vaccine in respiratory syncytial virus infection (RSV), sponsored by MAXVAX Biotechnology. Primary endpoints: Neutralizing Antibodies against both the RSV-A and RSV-B subtypes at 24 months, Specific IgG Antibodies to RSV pre-F of both RSV-A and RSV-B subtypes at 24 months and 1 more. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
recombinant respiratory syncytial virus vaccine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT07618325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07618325.